Can New Drugs Drive J&J's Innovative Medicine Despite Stelara LOE?

2026-04-07 22:40:33

Abstract generation in progress

Johnson & Johnson’s Innovative Medicine unit is expected to see growth in Q1 2026 driven by key products like Darzalex and newer therapies, but faces significant pressure from the loss of exclusivity for Stelara and biosimilar competition. The company is introducing new drugs and indications, such as Inlexzoh/TAR-200, Imaavy, and Icotyde, to counteract these declines. Investors will focus on the performance of these new products and the impact of generic competition on older drugs.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.